STUDY DESIGN AND METHODS:
Plasma samples from 4232 donors were tested for B19V DNA by polymerase chain reaction. Reactive samples were confirmed and viral load determined. A transmission-risk model was used to estimate recipient risk, and the risk from community exposure was estimated using seroprevalence data.
RESULTS:
Two samples (0.0473%, 95% confidence interval [CI] 0.0130-0.172) confirmed positive for B19V DNA had a potentially infectious viral load of 10 5 IU/mL or higher. The estimated risk of a TT-B19V-associated significant complication was low overall at approximately 1 in 300,000 (95% CI, 1 in 82,000 to 1 in 1 million) fresh components transfused, with 3.1 (95% CI, 0.85-11.3) complications modeled per year. Among vulnerable recipient groups, the risk was higher than 1 in 15,000 patients, but the risk from community exposure far exceeded the transfusion risk for all patient and age groups.
CONCLUSION:
In the context of the small contribution of transfusion to the burden of B19V disease, the significant costs that would be incurred by any strategy to reduce the risk, and given the significant uncertainties and likely overestimation of the risk, we conclude TT-B19V is a tolerable risk to blood safety, despite being high for some vulnerable recipient groups.
P arvovirus B19 (B19V) is a community-acquired respiratory infection most frequently observed among children and their contacts; by early adulthood, approximately half of the population in most countries has been exposed and is immune. 1 Infections occur in all seasons, with outbreaks both seasonal and cyclical, with two epidemic and two endemic years commonly described. 2, 3 Most B19V infections in adults are asymptomatic or associated with only nonspecific flulike symptoms from approximately 1 week after infection. 4, 5 A second-phase illness of rash and/or arthropathy may occur from approximately Day 17 after infection. 1, 5 B19V replication is specific to and cytotoxic for erythroid progenitor cells, leading to a significant decrease in or absence of reticulocytes. 1 Owing to the long life span of erythrocytes, the clinical effect is usually minimal in immunocompetent individuals, although anemia and/or other cytopenias may occur. 1 However, where there is preexisting high red cell turnover, increased hematopoietic demand, and/or impaired immunity, infection may be severe (Table 1) . [6] [7] [8] [9] [10] [11] manifestations in immunocompetent individuals including encephalitis and cardiac diseases such as myocarditis.
1
Transfusion transmissibility by fresh blood components is well established, with a B19V DNA level of 10 5 IU/mL generally considered the corresponding potential infectious dose. 12 A small number of case reports showed that transmission can occur at lower levels (see review 12 ), but three large look-back studies reported either no transmissions 13, 14 or a single transmission 15 from components with B19V DNA levels lower than 10 5 IU/L. Although detectable viremia may last for more than a year, 12 the period of potentially infectious viremia is comparatively short and likely to be about 12 weeks or less. 16 Given that B19V is a common infection, yet there have been relatively few reported cases of transfusion-transmitted (TT) B19V (TT-B19V), it appears that transfusion is an inefficient mode of transmission. This is likely due to several factors: concomitant neutralizing B19V immunoglobulin (Ig)G in donors (more likely at viral loads below the potential infectious dose, that is, where the donor has persistent low-level infection); high seroprevalence among recipients; co-transfusion of other blood products containing neutralizing antibodies (which fortunately is more likely for immunosuppressed patients who are vulnerable to B19V); and failure to recognize and/or lack of clinical relevance of most TT-B19V cases due to their asymptomatic or nonspecific nature.
12
Fresh component donations are not tested for B19V in Australia, similar to the vast majority of blood services internationally. Where testing is undertaken, strategies include using nucleic acid amplification (NAT) technology to test for B19V in minipools (Germany/Austria), 16 providing "B19V-safe" components from donors who have been positive for B19V IgG for at least 6 months upon request (the Netherlands), 3 and testing all donations for B19V antigen (Japan).
Potential mitigation of the B19V risk for fresh component recipients is being debated by the transfusion community. 12 In
Australia, consideration of this issue was prompted by the occurrence of three probable cases of TT-B19V between 2014 and 2017. On two separate occasions, a B19V-positive transfusion recipient was reported to the Australian Red Cross Blood Service (Blood Service), and it was identified that the archive sample from one of the source donations was positive for B19V DNA. The donation viral loads were higher than 10 5 and approximately 10 6 IU/mL of B19V DNA. Look-back revealed a third recipient who also developed symptoms and results compatible with TT-B19V after receiving a component from the donation with a viral load higher than 10 5 IU/mL. All three patients fully recovered, and all cases were classified as probable transfusion transmissions because sequencing is unable to confirm or reject transfusion transmission in the absence of a large sample of unrelated circulating strains. 17 A report of the 2017 case has been submitted for publication. This study had three objectives: to determine the B19V DNA prevalence among blood donors, in total and with levels 10 5 IU/mL or higher; to model the risk of TT-B19V-associated significant complications among recipients of fresh blood components, for specific vulnerable groups and other recipients; and to place the risk in context and assess options for risk management using the principles of the Risk-Based Decision-Making Framework for Blood Safety (information at https://allianceofbloodoperators.org/aboresources/risk-based-decision-making.aspx).
MATERIALS AND METHODS
B19V DNA prevalence study Plasma samples were previously collected from all presenting whole blood donors for another, larger research project. 18 Where adequate volume remained following testing, a subset of these samples was selected, totaling 4232 samples collected between June and September 2016. The samples were stratified by blood donation processing center, at a proportion consistent with the number of collections processed at each. Basic demographic data (age, sex, and area ‡ Pooled platelets potentially have four donor exposures, but 70% of the total component volume is platelet additive solution. Therefore, they are assigned the risk of one donor exposure given the dilution results in a smaller infectious dose. § As per assumptions, three different rates were used for SOT and HSCT. The "low" estimate for complications combines the low rate for each (i.e., 10% for SOT and 1% for HSCT).
of residence), donation date, and time since last donation were obtained for each sample before sample deidentification and assignment of a unique study number. Ethical approval was obtained from the Blood Service Human Research Ethics Committee. Viral DNA was extracted and samples were tested in singlicate for the presence of B19V DNA (Biomérieux Parvovirus B19 R-gene assay; Biomérieux Pty Ltd.) as per the manufacturer's instructions. Initially reactive samples were tested in duplicate, and confirmatory B19V DNA testing was performed by Pathology Queensland of the Queensland Health Department using an in-house polymerase chain reaction. For samples containing B19V DNA, the viral load was quantified with reference to the World Health Organization International Standard for B19V (Paul-Ehrlich-Institut), and sequencing was undertaken. See Supporting Information for detailed methodology of the prevalence study (Appendix S1).
Risk modeling
A model was developed using the prevalence of B19V DNA at levels of 10 5 IU/mL or higher to estimate the yearly risk of TT-B19V-associated significant complications in recipients of fresh blood components in Australia. The modeling was based on the following assumptions (justified in Supporting Information, Appendix S2):
1. The B19V DNA prevalence estimated in this study represents the steady-state prevalence in fresh components. 2. B19V will only be transmitted to susceptible (nonimmune) recipients if the viral load in a component is 10 5 IU/mL or higher, and this will occur regardless of co-transfused antibodies. 3. B19V immunity among Australian transfusion recipients reflects the findings of a B19V IgG seroprevalence study recently performed in blood donors and a pediatric cohort. 19 4. The age distribution of transfusion recipients in the Netherlands 20 is applicable to Australia.
5. The frequency of significant complications attributable to B19V infection in the general population is 0.5%. 
The burden of B19V-associated complications is much
lower for hematopoietic stem cell transplant than SOT recipients. 33 The number of fresh components (RBCs, platelets, and clinical plasma) transfused per year was obtained from internal Blood Service databases. The average annual infection rate (i.e., the frequency of community-acquired infection) was estimated by expressing the increase in seroprevalence between age groups as a percentage of the remaining susceptible population. The population-attributable fraction (PAF) represents the proportional reduction in population disease that would occur if the risk from a particular exposure was reduced to zero. B19V PAFs for the transfused population were estimated by dividing the risk associated with transfusion or community exposure by the sum of both risks for the same group.
Statistical analyses
Confidence intervals (CIs) for the prevalence of infectious donations were calculated using the Wilson score interval and used in calculating the upper and lower modeled risk estimates.
RESULTS
B19V DNA was confirmed in 10 samples (0.236%, 95% CI, 0.128-0.434). Most of the positive samples were from males (60%) and from the Melbourne Processing Centre (MPC) (50%). The mean donor age was approximately 40 years, which is consistent with whole blood donors in general. 47 The mean B19V DNA level was log 3.50 IU/mL (3.17 × 10 3 IU/mL), with a standard deviation of log 1.60 IU/mL (39.9 IU/mL). Two samples were identified with a B19V DNA level of 10 5 IU/mL or higher (5.77 × 10 5 and 1.77 × 10 6 IU/mL, respectively), giving an infectious donation rate of 1 in 2116 (0.0473%, 95% CI, 0.0130-0.172). Three of 12 samples were successfully sequenced, and pairwise alignment demonstrated 99.6% pairwise identity to the B19V genotype 1 reference sequence (see Supporting Information, Appendix S3).
The overall risk of a TT-B19V-associated significant complication per fresh component transfused was conservatively estimated to be low at approximately 1 in 300,000 components (95% CI, 1 in 82,000 to 1 in 1 million), with a combined modeled number of complications of 3.1 (95% CI, 0.85-11.3) per year. For pregnant women, transplant recipients, and patients with HHAs, the risk per recipient or component exceeded 1 in 15,000, whereas for other ("general") recipients it was less than 1 in 1 million components ( Table 2) . Analysis of transplant recipients by organ type and individual patient risk for patients with SCD was also performed (Appendix Tables 5 and 6 ). The risk of community exposure and associated complications was much higher for all patient and age groups (Table 3) , which is reflected in the PAFs in the transfused population associated with community exposure: more than 98% for both adult and pediatric general transfusion recipients; 80.4% for transfused pregnant women and 99.97% among all pregnant women; 82.6% and 95% for transfused adult and pediatric SOT recipients, respectively; and among patients with HHAs, more than 95% for sporadically transfused patients of all age groups, more than 80% for transfusion-dependent children, and 68% for transfusion-dependent adults.
DISCUSSION
The prevalence of confirmed B19V DNA in this study was 0.236% (1 in 423 donations), but the prevalence of assumed potentially infectious donations was 0.0473% (1 in 2116 donations). Although one donation had a DNA level approaching 10 5 IU/mL (8.78 × 10 4 IU/mL), the remainder of the positive results had low viral loads (96 to 6.8 × 10 3 IU/mL) that are likely prolonged viremia with neutralizing antibodies. Given our conservative estimate of 100% transmissibility, our viral load data support using 10 5 IU/mL as the best estimate of potentially infectious donations to perform the risk analysis. Sample collection partially overlapped with the peak B19V period in Australia (late winter and spring). 2 Despite the MPC collections occurring in early winter, the three highest viral loads were identified from this processing center. MPC processes collections from Tasmania, South Australia, and Victoria, southern states with a documented higher B19V seroprevalence in Australia.
19
Higher donor infection rates in particular areas may increase the transmission risk, although for immunocompetent recipients this may be offset by the increased prevalence of immunity. Owing to the lack of national surveillance for B19V in Australia, it is unknown whether the year of this study was a B19V epidemic year, in which case these findings are likely to be an overestimation of the typical blood safety risk. Nevertheless, the rate of detectable viremia was lower than that reported from comparable countries such as the United States (0.84%) and United Kingdom (0.9%). 48 Our estimate of potentially infectious viremia is also consistent with international estimates, which range from 0.006% in the Netherlands for levels of 10 6 IU/mL or higher, 3 The Blood Service considers that risks for moderate severity outcomes such as those estimated in this assessment are tolerable if less than 1 in 500,000. The overall risk of 1 in 300,000 is higher than this threshold. However, adult and pediatric recipients would have to receive in excess of 17 or 55 blood components, respectively, to equal the risk of infection from 1 year of community exposure. Additionally, the risk modeling was conservative and likely overestimates the risk in regard to the prevalence of infectious DNA, lack of transmission factor, possible co-transfusion of neutralizing antibodies, and significant uncertainties in recipient outcomes. Similarly, the risk for individual patients in vulnerable groups is high, but the absolute numbers of significant complications per year are relatively low, the community exposure risk is much higher, and there are additional mitigating factors and uncertainties specific to each group. For pregnant women, the risk period is very short. The blood exposure of organ transplant recipients is almost certainly lower than assumed due to widespread uptake of patient blood management techniques in Australia, and they also carry a risk of B19V reactivation. The community-associated PAF for patients with HHAs may be underestimated because these patients are more likely to come into contact with other patients or family affected by HHAs, who are highly infectious during B19V-attributable TAC. 1 However, most SCD patients experience TAC in their lifetime 46 (which is easily managed by a treatment they receive regularly), and therefore risk mitigation would not prevent but only delay a complication for these patients. This study has demonstrated that the risk of TT-B19V-associated complications may not fall into the predefined tolerable range and that some recipient groups are at high risk. In Australia, the following risk management options have been considered:
1. Accept the risk without further risk management. The risk to the vast majority of recipients is negligible, and the significant complications that may occur in organ transplant recipients and patients with HHAs are easily treated and/or associated with generally good outcomes. This is not the case in pregnancy, but because transfusion is so rarely required for this group, 25 TT-B19V-attributable fetal loss would only occur approximately once every 39 years (compared with once every few days from community exposure). Additionally, the risk of infection from community exposure is very high for all susceptible recipients and not feasibly prevented. There are no recommendations aimed at avoiding exposure for patients at higher risk of disease from any advisory group. 49, 50 In this context and given that any other option will incur significant cost, the risk may be endorsed as tolerable (as low as reasonably achievable) if all other options have been considered. 2. Targeted testing for B19V. Targeting mitigation efforts to one or more of the vulnerable recipient groups at high risk was considered. However, managing dual-stock inventory is associated with increased costs, workloads, and risk of errors, particularly when there are competing requirements for the same populations (e.g., recipients who are cytomegalovirus negative or have red cell antibodies). This may not be a feasible option given these issues and the considerable uncertainties in the modeled estimates. 3. Universal testing for B19V. Universal testing for B19V would substantially decrease the risk for all recipients including those not specifically considered in this assessment (e.g., patients with immunosuppression secondary to malignancy and treatment). Currently there are too many uncertainties regarding the transmission risk of blood components and adverse outcomes in recipients to allow for an informed decision. It is known that universal screening would incur significant cost while not addressing most of the transfused population's burden of B19V disease (from community exposure).
Pathogen inactivation (PI). Effective RBC PI has not yet
been realized, and there is no licensed PI system in Australia. In addition PI was not shown to be definitively protective against TT-B19V in fresh blood components. 51 5. Perform further studies and analyses to reduce uncertainties. If stakeholder feedback indicates that the current B19V blood safety risk is not perceived as tolerable, further studies and analyses would allow for an informed decision on the appropriate risk management strategy. These should include studies of DNA prevalence (on a larger scale, with donor-triggered look-back where relevant), vulnerable patients with confirmed B19V (including outcomes and recipient-triggered look-back where relevant), and the transfusion requirements of vulnerable patient groups in Australia. Subsequently, a more extensive blood safety risk analysis should be conducted including economic analysis, assessment of the operational and logistical feasibility of options 2 and 3, and consultation with stakeholders.
We acknowledge that the uncertainty in the modeling precludes implementing a strategy with significant cost implications (i.e., testing or PI) because this requires confident parameters on the prevalence, transmissibility, and recipient complications to enable. Therefore, only options 1 (accept the risk) and 5 (further studies) can be reasonably concluded as options from this risk assessment, while noting that conservative assumptions were used in modeling and the assessment is likely an overestimate of the blood safety risk. Australia, unlike many countries, does not routinely perform B19V testing for donations with a source plasma component, except for manufacture of RhD immunoglobulin. For countries where testing and its associated cost is already implemented for source plasma, our conclusion to accept the risk may not be applicable because the additional cost of other options may be small. Blood transfusion is a life-saving treatment and contributes only a small minority of the burden of B19V disease, even in transfused recipients. Because of this small contribution, the significant cost incurred by any strategy to reduce the risk associated with TT-B19V and the fact that successful treatment can prevent complications when recognized, our recommendation is to increase clinician awareness of the possibility of B19V in vulnerable patients while accepting B19V as a "tolerable risk" to blood safety. In the event of a clinically compatible illness, this will allow prompt diagnosis and treatment where indicated. The Blood Service will use this research to seek formal stakeholder feedback on these recommendations.
